Adult human liver contains intermediate-type proteasomes with different enzymatic properties

Annals of Hepatology

Volumn 13, Issue 4, 2014, Pages 429-438

  Gohlke, Sabrina ^a   Kloß, Alexander ^a   Tsokos, Michael ^a   Textoris Taube, Kathrin ^a   Keller, Christin ^a   Kloetzel, Peter Michael ^a   Dahlmann, Burkhardt ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

HuH7 cells; Proteasome subpopulations; Proteasome subtypes; Proteolytic activities

Indexed keywords

20S PROTEASOME; CASPASE; CHYMOTRYPSIN; PROTEASOME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LIVER; LIVER CANCER CELL LINE; PROTEIN DEGRADATION; CELL LINE; ELECTROPHORESIS; ENZYMOLOGY; ERYTHROCYTE; METABOLISM; SPLEEN;

CELL LINE; ELECTROPHORESIS; ERYTHROCYTES; HUMANS; LIVER; PROTEASOME ENDOPEPTIDASE COMPLEX; SPLEEN;

EID: 84902386897     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30850-6     Document Type: Article

References (58)

1. Tavill AS. The synthesis and degradation of liver-produced proteins. Gut 1972: 13: 225-41.
2. Yin XM, Ding WX, Gao W. Autophagy in the liver. Hepatology 2008: 47: 1773-85.
3. Schimke RT, Doyle D. Control of enzyme levels in animal tissues. Annu Rev Biochem 1970: 39: 929-76.
4. Simpson MV. The release of labeled amino acids from the proteins of rat liver slices. J Biol Chem 1953: 201: 143-54.
5. DeMartino GN, Goldberg AL. Identification and partial purification of an ATP-stimulated alkaline protease in rat liver. J Biol Chem 1979: 254: 3712-5.
6. Tanaka K, Ii K, Ichihara A, Waxman L, Goldberg AL. A high molecular weight protease in the cytosol of rat liver. I. Purification, enzymological properties, and tissue distribution. J Biol Chem 1986: 261: 15197-203.
7. Tanaka K, Yoshimura T, Ichihara A, Kameyama K, Takagi T. A high molecular weight protease in the cytosol of rat liver. II. Properties of the purified enzyme. J Biol Chem 1986: 261: 15204-7.
8. Umana CR. Protein degradation at neutral pH. Possible enzymic and control mechanisms. Proc Soc Exp Biol Med 1971: 138: 31-8.
9. Ciechanover A. The ubiquitin proteolytic system: from an idea to the patient bed. Proc Am Thorac Soc 2006: 3: 21-31.
10. Groll M, Bochtler M, Brandstetter H, Clausen T, Huber R. Molecular machines for protein degradation. Chembiochem 2005: 6: 222-56.
11. Ebstein F, Kloetzel PM, Kruger E, Seifert U. Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell Mol Life Sci 2012: 69: 2543-58.
12. Yewdell JW. Immunoproteasomes: regulating the regulator. Proc Natl Acad Sci U S A 2005: 102: 9089-90.
13. Klare N, Seeger M, Janek K, Jungblut PR, Dahlmann B. Intermediate-type 20 S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation. J Mol Biol 2007: 373: 1-10.
14. Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 2005: 15: 27-33.
15. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999: 68: 1015-68.
16. Arribas J, Castano JG. Kinetic studies of the differential effect of detergents on the peptidase activities of the multicatalytic proteinase from rat liver. J Biol Chem 1990: 265: 13969-73.
17. Djaballah H, Rowe AJ, Harding SE, Rivett AJ. The multicatalytic proteinase complex (proteasome): structure and conformational changes associated with changes in proteolytic activity. Biochem J 1993: 292: 857-62.
18. Ishiura S, Yamamoto T, Nojima M, Sugita H. Ingensin, a fatty acid-activated serine proteinase from rat liver cytosol. Biochim Biophys Acta 1986: 882: 305-10.
19. Yamamoto T, Nojima M, Ishiura S, Sugita H. Purification of the two forms of the high-molecular-weight neutral proteinase ingensin from rat liver. Biochim Biophys Acta 1986: 882: 297-304.
20. Rivett AJ. Purification of a liver alkaline protease which degrades oxidatively modified glutamine synthetase. Characterization as a high molecular weight cysteine proteinase. J Biol Chem 1985: 260: 12600-6.
21. Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, Drews O, Lu H, et al. Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues. Mol Cell Proteomics 2009: 8: 302-15.
22. Tomek W, Buri J, Vallon R, Schmid HP. Large-scale purification of prosomes from calf's liver. J Chromatogr 1990: 521: 221-9.
23. Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, Tsukihara T. The structure of the mammalian 20S proteasome at 2. 75 A resolution. Structure 2002: 10: 609-18.
24. Sato S, Shiratsuchi A. 'Chymotrypsin-like' activity of chicken liver multicatalytic proteinase resides in the smallest subunit. Biochim Biophys Acta 1990: 1041: 269-72.
25. Klinkradt S, Naude RJ, Muramoto K, Oelofsen W. Purification and characterization of proteasome from ostrich liver. Int J Biochem Cell Biol 1997: 29: 611-22.
26. Mason RW. Characterization of the active site of human multicatalytic proteinase. Biochem J 1990: 265: 479-84.
27. Seol JH, Park SC, Ha DB, Chung CH, Tanaka K, Ichihara A. Na+, K+-specific inhibition of protein and peptide hydrolyses by proteasomes from human hepatoma tissues. FEBS Lett 1989: 247: 197-200.
28. Liepe J, Mishto M, Textoris-Taube K, Janek K, Keller C, Henklein P, Kloetzel PM, et al. The 20S proteasome splicing activity discovered by SpliceMet. PLoS Comput Biol 2010: 6: e1000830.
29. Gohlke S, Mishto M, Textoris-Taube K, Keller C, Giannini C, Vasuri F, Capizzi E, et al. Molecular alterations in proteasomes of rat liver during aging result in altered proteolytic activities. Age (Dordr) 2013: doi: 10. 1007/s11357-013-9543-x.
30. Mishto M, Goede A, Taube KT, Keller C, Janek K, Henklein P, Niewienda A, et al. Driving forces of proteasome-catalyzed peptide splicing in yeast and humans. Mol Cell Proteomics 2012: 11: 1008-23.
31. Schmidt F, Dahlmann B, Janek K, Kloss A, Wacker M, Ackermann R, Thiede B, et al. Comprehensive quantitative proteome analysis of 20S proteasome subtypes from rat liver by isotope coded affinity tag and 2-D gel-based approaches. Proteomics 2006: 6: 4622-32.
32. Kloss A, Meiners S, Ludwig A, Dahlmann B. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc Res 2009: 85: 367-75.
33. Wehren A, Meyer HE, Sobek A, Kloetzel PM, Dahlmann B. Phosphoamino acids in proteasome subunits. Biol Chem 1996: 377: 497-503.
34. Sixt SU, Alami R, Hakenbeck J, Adamzik, M, Kloss A, Costabel U, Jungblut PR, et al. Distinct Proteasome Subpopulations in the Alveolar Space of Patients with the Acute Respiratory Distress Syndrome. Mediators of Inflammation 2012: doi: 10. 1155/2012/204250.
35. Dechavanne V, Vilbois F, Glez L, Antonsson B. Purification and separation of the 20S immunoproteasome from the constitutive proteasome and identification of the subunits by LC-MS. Protein Expr Purif 2013: 87: 100-10.
36. Cui Z, Scruggs SB, Gilda JE, Ping P, Gomes AV. Regulation of cardiac proteasomes by ubiquitination, SUMOylation, and beyond. J Mol Cell Cardiol 2013: doi: 10. 1016/j. yjmcc. 2013. 10. 008.
37. Zong C, Gomes AV, Drews O, Li X, Young GW, Berhane B, Qiao X, et al. Regulation of murine cardiac 20S proteasomes: role of associating partners. Circ Res 2006: 99: 372-80.
38. Wang D, Fang C, Zong NC, Liem DA, Cadeiras M, Scruggs S B, Yu H, et al. Regulation of Acetylation Restores Proteolytic Function of Diseased Myocardium in Mouse and Human. Mol Cell Proteomics 2013.
39. Chapiro J, Claverol S, Piette F, Ma W, Stroobant V, Guillaume B, Gairin JE. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J Immunol 2006: 176: 1053-61.
40. Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk C J, Groettrup M, Groll M. Immuno-and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 2012: 148: 727-38.
41. Adachi S, Okuno M, Matsushima-Nishiwaki R, Takano Y, Kojima S, Friedman SL, Moriwaki H, et al. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 2002: 35: 332-40.
42. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009: 284: 11121-33.
43. Harada M, Kumemura H, Omary MB, Kawaguchi T, Maeyama N, Hanada S, Taniguchi E, et al. Proteasome inhibition induces inclusion bodies associated with intermediate filaments and fragmentation of the Golgi apparatus. Exp Cell Res 2003: 288: 60-9.
44. Harada M, Sakisaka S, Terada K, Kimura R, Kawaguchi T, Koga H, Kim M, et al. A mutation of the Wilson disease protein, ATP7B, is degraded in the proteasomes and forms protein aggregates. Gastroenterology 2001: 120: 967-74.
45. Stevenson NJ, Bourke NM, Ryan EJ, Binder M, Fanning L, Johnston J A, Hegarty JE, et al. Hepatitis C virus targets the interferon-alpha JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes. FEBS Lett 2013: 587: 1571-8.
46. Zoeger A, Blau M, Egerer K, Feist E, Dahlmann B. Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin Chem 2006: 52: 2079-86.
47. Khan S, van den Broek M, Schwarz K, de Giuli R, Diener PA, Groettrup M. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol 2001: 167: 6859-68.
48. Vasuri F, Capizzi E, Bellavista E, Mishto M, Santoro A, Fiorentino M, Capri M, et al. Studies on immunoproteasome in human liver. Part I: absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis. Biochem Biophys Res Commun 2010: 397: 301-6.
49. Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch M P. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A 2010: 107: 18599-604.
50. Bardag-Gorce F, Venkatesh R, Li J, French BA, French SW. Hyperphosphorylation of rat liver proteasome subunits: the effects of ethanol and okadaic acid are compared. Life Sci 2004: 75: 585-97.
51. Drews O, Wildgruber R, Zong C, Sukop U, Nissum M, Weber G, Gomes AV, et al. Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol Cell Proteomics 2007: 6: 2021-31.
52. Brooks P, Fuertes G, Murray RZ, Bose S, Knecht E, Rechsteiner MC, Hendil KB, et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 2000: 346 Pt 1: 155-61.
53. Rivett AJ, Palmer A, Knecht E. Electron microscopic localization of the multicatalytic proteinase complex in rat liver and in cultured cells. J Histochem Cytochem 1992: 40: 1165-72.
54. Eang R, Girbal-Neuhauser E, Xu B, Gairin EJ. Characterization and differential expression of a newly identified phosphorylated isoform of the human 20S proteasome ß7 subunit in tumor vs. normal cell lines. Fund Clin Pharmacol 2009: 23: 215-24.
55. Berko D, Tabachnick-Cherny S, Shental-Bechor D, Cascio P, Mioletti S, Levy Y, Admon A, et al. The direction of protein entry into the proteasome determines the variety of products and depends on the force needed to unfold its two termini. Mol Cell 2012: 48: 601-11.
56. Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000: 174: 21-34.
57. Williams GM, Iatropoulos MJ. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol Pathol 2002: 30: 41-53.
58. French BA, Oliva J, Bardag-Gorce F, French SW. The immunoproteasome in steatohepatitis: its role in Mallory-Denk body formation. Exp Mol Pathol 2011: 90: 252-6.